Canyon Ridge Legal represents victims across the nation who have been stricken with cancer after taking Zantac. If you or a loved one has cancer that may be linked to Zantac, you may be entitled to damages from the makers of Zantac.
On April 1, 2020 the U.S. Food and Drug Administration (FDA) issued a request that manufacturers immediately withdraw all prescription and over-the-counter (OTC) ranitidine drugs such as Zantac from the market. The FDA further advised consumers to stop taking (OTC) ranitidine medications in any form.
Prior to the recall, Zantac was one of the most widely used medications for the treatment of heartburn, acid reflux and acid related digestive issues and was available over the counter here in the United States. The FDA began recalling Zantac and ranitidine medications in September 2019 due to the presence of a known carcinogen, N-nitrosodimethylamine, more commonly known as NDMA.
NDMA is an extremely toxic substance and was formerly used as a key ingredient in rocket fuel. NDMA is so toxic that it’s commonly used by scientists to induce cancer in lab rats when necessary for research purposes. According to WebMD, when pregnant mice were fed NDMA in the lab, their babies were either born dead or died shortly after birth.
Lawsuits have been filed against the makers of Zantac claiming the side effects and range of injuries from ingesting NDMA are significant. Taking Zantac has been linked to the following type of cancer.
Every year, doctors wrote more than 15 million prescriptions for Zantac. Countless additional heartburn patients buy it over the counter in the non-prescription form. In February 2020, the U.S. Judicial Panel on Multidistrict Litigation (JPML) issued an Initial Transfer Order creating Multidistrict Litigation 2924 (MDL 2924) to handle the massive number of claims that will arise against Zantac over the coming months.
We will never share your information. Privacy Policy.
On September 13, 2019, the FDA initiated a recall of both prescription strength and over the counter Zantac due to findings that it contains NDMA. The investigation is ongoing to determine whether the medication was contaminated during the manufacturing process or if the NDMA is the result of a chemical reaction among the actual ingredients used to produce Zantac. In the summer of 2019, prior to the September recall, the FDA became aware of independent laboratory testing that found NDMA in ranitidine.
Further FDA testing confirmed that NDMA levels increase in ranitidine even under normal storage conditions. NDMA was found to increase significantly in samples stored at higher temperatures, including temperatures the product may be exposed to during distribution and handling by consumers. FDA testing also revealed that NDMA levels increase over time as the ranitidine product ages.
There is ongoing litigation against the manufacturers of Zantac and it’s not too late for you to join. Canyon Ridge Legal can help you recover compensation for your injuries. Complete the form below and someone from our team will contact you right away for a free case evaluation.
According to a 2008 report by the World Health Organization (WHO), NDMA is a byproduct created through the breakdown of dimethylhydrazine, a component used to make rocket fuel. NDMA is also found in pesticides. The WHO concluded through experimental testing that NDMA is a potential carcinogen and causes cancer through the liver function.
According to a report released by the U.S. Environmental Protection Agency (EPA), NDMA can be produced as a manufacturing byproduct of tanneries, pesticides, rubber and tire manufacturers and fish processing facilities.
In 2018, there were over 25 million prescriptions for ranitidine products according to Bloomberg research.
